Efficacy and Safety of Telitacicept in Early SLE
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Drug: Standard of Care
- Registration Number
- NCT05899907
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with early stage of SLE .
- Detailed Description
This is a phase 4, multicentre, randomised, double-blind, open-labeled study to evaluate the efficacy and safety of telitacicept in adult subjects with active early stage of SLE (disease duration less than 2 years).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 180
- Clinical diagnosis of SLE according to the 1997 American College of Rheumatology (ACR) classification criteria or 2019 EULAR/ACR classification criteria
- 18-65 years of age
- body weight 45-90kg
- antinuclear antibody titers ≥1:80, and/ or anti-double-stranded DNA antibodies
- SLEDAI-2K score ≥8 scores
- Disease duration less than 2 years (defined as the duration between the first appearance of any symptom/sign attributed to SLE and baseline)
- A stantard therapy for at least 30d for patients who are not treatment-naive
- Negative pregnancy test for child-bearing women at screening and baseline
- Provide written informed consent
- Known to be allergic to Prednisone Acetate, Meprednisone, Hydroxychloroquine, and Immunosuppressants including Mycophenolate Mofetil, Cyclophosphamide,et al
- Active serious neuropsychiatric systemic lupus erythematosus or other severe situations of SLE who need pulse steroid treatment
- severe lupus nephritis: 24hUP more than 6g, serum creatinine > 221umol/L
- History of severe active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis) requiring intervention within 60 days of baseline (Day 1)
- Abnormal liver function (ALT or AST is 2 times higher than normal)
- Baseline IgG below the lower limit of the normal range
- Pregnancy or breastfeeding women
- Have a history of malignant tumors
- Have any serious acute, chronic or recurrent infectious disease (such as pneumonia or active stage of pyelitis, recurrent pneumonia, chronic bronchiectasis and tuberculosis)
- Chronic infections, such as Hepatitis B virus or hepatitis B and C and HIV
- Cardiac insufficiency with metabolic imbalance or severe high blood pressure (systolic pressure > 160mmHg or diastolic pressure > 100mmHg) or diabetics
- Active hemorrhage or peptic ulcer
- With other concommitant autoimmune disease;
- Receipt of B-cell-targeted therapy (including belimumab) within 1 year before randomization
- Receipt of IVIG within 28 days before randomization
- Receipt of TNF inhibitor, IL-1R inhibitor or plasma exchange therapy within 90 days before randomization
- Participated in other drugs clinical trials within 4 weeks.
- Receipt of live vaccine within 4 weeks before randomization
- Receipt of COVID-19 vaccine within 4 weeks before randomization
- Subjects who in the opinion of the investigator are not suitable to participate
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment group Standard of Care Standard of care plus Telitacicept 160 mg sc per week; after week 12, the dose can be reduced to 80 mg per week due to safety considerations. Control group Standard of Care Standard of care Treatment group Telitacicept Standard of care plus Telitacicept 160 mg sc per week; after week 12, the dose can be reduced to 80 mg per week due to safety considerations.
- Primary Outcome Measures
Name Time Method Proportion of LLDAS in week 24 week 24 Lupus low disease activity status (LLDAS) was defined as SLEDAI-2K ≤4, no activity in any major organ, no new disease activity feature, PGA ≤1, prednisone ≤7.5 mg/day, and allowance for maintenance of IS and antimalarials
- Secondary Outcome Measures
Name Time Method Improvement in SLEDAI-2K week 24 and 52 Proportion of patients with SLEDAI-2K scores improvement ≥4 compared with baseline
Number of participants with Adverse Events up to week 52 An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A SAE is any untoward medical occurrence that at any dose resulting in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant and which the investigator regards as serious based on appropriate medical judgment.
Disease flare up to week 52 Proportion of patients suffer from SLE flare
Change in PGA week 24, 52 PGA: physician global assesment(0-3)
Proportion of LLDAS in week 12 week 12 Lupus low disease activity status (LLDAS) was defined as SLEDAI-2K ≤4, no activity in any major organ, no new disease activity feature, PGA ≤1, prednisone ≤7.5 mg/day, and allowance for maintenance of IS and antimalarials
Improvement in serological indices week 24, 52 Improvement in anti-dsDNA antibody titers, C3, C4, T cell and B cell subsets and IgG, IgA, IgM compared with baseline
Trial Locations
- Locations (20)
Qilu Hospital of Shandong University
🇨🇳Jinan, China
The First Affiliated Hospital of Soochow University
🇨🇳Suzhou, China
First Affiliated Hospital of Xinjiang Medical University
🇨🇳Urumqi, China
Weifang People's Hospital
🇨🇳Weifang, China
Tongji Hospital, Tongji Medical College,
🇨🇳Wuhan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, China
the First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, China
Chinese Academy of Medical Sciences & Peking Union Medical College
🇨🇳Beijing, Beijing, China
Fuyang People's Hospital
🇨🇳Fuyang, China
Nanfang Hospital, Southern Medical University
🇨🇳Guanzhou, China
Peking University Third Hospital
🇨🇳Beijing, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
the First People's Hospital of Yunnan Province
🇨🇳Kunming, China
The Second Affiliated Hospital of Lanzhou University
🇨🇳Lanzhou, China
The Affiliated Hospital of Nantong University
🇨🇳Nantong, China
the Affiliated Hospital of Qingdao University
🇨🇳Qingdao, China
The Second Hospital of Hebei Medical University
🇨🇳Shijiazhuang, China
Shanxi Baiqiuen Hospital
🇨🇳Taiyuan, China
Wuxi Second People's Hospital
🇨🇳Wuxi, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhenzhou, China